| scholarly article | Q13442814 |
| P50 | author | Wolfgang Wick | Q2591750 |
| Michael Weller | Q2779469 | ||
| Guido Reifenberger | Q30004009 | ||
| Gabriele Schackert | Q61228246 | ||
| Jörg Felsberg | Q66360667 | ||
| Manfred Westphal | Q88727916 | ||
| Bettina Hentschel | Q116792811 | ||
| German Glioma Network | Q117285678 | ||
| P2093 | author name string | Markus Loeffler | |
| Torsten Pietsch | |||
| Oliver Schnell | |||
| Matthias Simon | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glioblastoma | Q282142 |
| P304 | page(s) | 1342-1350 | |
| P577 | publication date | 2012-01-11 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Predictive impact of MGMT promoter methylation in glioblastoma of the elderly | |
| P478 | volume | 131 |
| Q92705399 | 18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma |
| Q48901436 | A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients |
| Q57022593 | A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas |
| Q38317424 | Assessing MGMT methylation status and its current impact on treatment in glioblastoma. |
| Q39556985 | Biomarkers classification and therapeutic decision-making for malignant gliomas |
| Q26795767 | Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions |
| Q41870675 | Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. |
| Q41015742 | Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients--yes, but how? |
| Q47804454 | Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients. |
| Q64930362 | Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. |
| Q61443962 | Combining multimodal imaging and treatment features improves machine learning-based prognostic assessment in patients with glioblastoma multiforme |
| Q55052526 | Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide). |
| Q26996421 | DNA methylation biomarkers: cancer and beyond |
| Q38650593 | DNA methylation profiles in cancer diagnosis and therapeutics. |
| Q53739720 | Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. |
| Q39876681 | Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. |
| Q38743138 | Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. |
| Q38461565 | Diagnostic, prognostic and predictive relevance of molecular markers in gliomas |
| Q48128887 | Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics. |
| Q35638372 | Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis |
| Q89559170 | Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma |
| Q37660295 | EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma |
| Q38598949 | Effect of temozolomide on survival in elderly patients with glioblastoma and impaired performance status: a propensity score-matching analysis |
| Q62491509 | Emerging Applications of Artificial Intelligence in Neuro-Oncology |
| Q90473187 | Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1 |
| Q36289595 | Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas |
| Q57786867 | Gene Promoter Methylation Status - Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas |
| Q47107733 | Glioblastoma Treatment in the Elderly |
| Q38653138 | Glioblastoma care in the elderly. |
| Q47827482 | Glioblastoma in elderly patients: solid conclusions built on shifting sand? |
| Q92446747 | Glioblastoma in the elderly: making sense of the evidence |
| Q40698810 | Glioblastoma multiforme in the very elderly |
| Q37388217 | High-grade glioma in elderly patients: can the oncogeriatrician help? |
| Q97543212 | Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trial |
| Q64098295 | Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF) |
| Q38120474 | Imaging genomic mapping in glioblastoma |
| Q41435886 | Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients. |
| Q38298124 | Incorporation of biomarkers in phase II studies of recurrent glioblastoma |
| Q42364418 | Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis |
| Q49979233 | MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals |
| Q36240860 | MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status |
| Q48656685 | MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma |
| Q34166477 | MGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study |
| Q34525704 | MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response |
| Q35803479 | MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma |
| Q35827916 | MGMT testing allows for personalised therapy in the temozolomide era. |
| Q38218848 | MGMT testing--the challenges for biomarker-based glioma treatment |
| Q41706326 | Management and treatment recommendations for World Health Organization Grade III and IV gliomas |
| Q34641001 | Management of elderly patients with gliomas |
| Q45980004 | Management of glioblastoma in elderly patients. |
| Q101051193 | Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital |
| Q41208796 | MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma. |
| Q38050966 | Molecular markers of glioma: an update on recent progress and perspectives |
| Q38551010 | Molecularly based management of gliomas in clinical practice |
| Q52643306 | Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study. |
| Q54948216 | Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. |
| Q89497366 | O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy |
| Q36288503 | O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas |
| Q90749072 | One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned? |
| Q47996641 | Optimal Therapies for Newly Diagnosed Elderly Patients with Glioblastoma |
| Q55461155 | Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients. |
| Q37526270 | Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients |
| Q104471814 | PLEKHG5 regulates autophagy, survival and MGMT expression in U251-MG glioblastoma cells |
| Q36866021 | Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain |
| Q37644692 | Patterns of diagnostic marker assessment in adult diffuse glioma: a survey of the European Confederation of Neuropathological Societies (Euro-CNS). |
| Q36344709 | Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice |
| Q37221207 | Personalized treatment strategies in glioblastoma: MGMT promoter methylation status |
| Q41612032 | Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival. |
| Q92545400 | Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients |
| Q38237337 | Predictive biomarkers investigated in glioblastoma. |
| Q35679476 | Predictive value of MGMT promoter methylation status in Asian and Caucasian patients with malignant gliomas: a meta-analysis |
| Q34256198 | Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM) |
| Q41282384 | Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). |
| Q42376082 | Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss |
| Q36124303 | Pro-apoptotic effects of rHSG on C6 glioma cells |
| Q34168829 | Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region |
| Q36107360 | Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis |
| Q38675705 | Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. |
| Q35815273 | Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma |
| Q92322332 | Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients |
| Q35004927 | Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis |
| Q34478948 | Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). |
| Q36542980 | Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them? |
| Q34706115 | Role of MGMT as biomarker in colorectal cancer |
| Q48774829 | Salvage therapy for recurrent glioblastoma multiforme: a multimodal approach combining fluorescence-guided resurgery, interstitial irradiation, and chemotherapy |
| Q50017177 | Semantic imaging features predict disease progression and survival in glioblastoma multiforme patients |
| Q35741879 | Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation. |
| Q92445913 | Survival in elderly glioblastoma patients treated with bevacizumab-based regimens in the United States |
| Q30251810 | Survival in glioblastoma: a review on the impact of treatment modalities. |
| Q37995906 | Temozolomide dosing regimens for glioma patients |
| Q38743781 | The Effect of Molecular Diagnostics on the Treatment of Glioma |
| Q27853156 | The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide |
| Q26746622 | The evolving roles and controversies of radiotherapy in the treatment of glioblastoma |
| Q38326253 | The potential for epigenetic analysis of paediatric CNS tumours to improve diagnosis, treatment and prognosis |
| Q39266259 | The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis |
| Q45835773 | The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis |
| Q46915446 | The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis |
| Q36299167 | The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. |
| Q28074595 | The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis |
| Q33757960 | The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort |
| Q41009177 | The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival |
| Q38233427 | Treating glioblastoma in the elderly. |
| Q38267992 | Treatment considerations for MGMT-unmethylated glioblastoma |
| Q47998543 | Treatment of Glioblastoma in Older Adults |
| Q30838145 | Treatment of glioblastoma in elderly patients. |
| Q38215192 | Treatment of malignant gliomas in elderly patients: a concise overview of the literature |
| Q55024234 | Tumor Necrosis Factor-Alpha (TNF-α-308 G>A) Polymorphism in High-grade Gliomas. |
| Q59329465 | Use of Mendelian andomization for dentifying isk actors for rain umors |
| Q38151582 | Using the molecular classification of glioblastoma to inform personalized treatment |
| Q37641708 | Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial |
| Q34325808 | ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma |
Search more.